Suggestions
Mehrrad Saadatmand, Ph.D.
Principal Scientist at Vertex Pharmaceuticals
Mehrrad Saadatmand, Ph.D. is a Principal Scientist at Vertex Pharmaceuticals with a diverse background in chemical engineering and research.12 He holds a Ph.D. in Chemical Engineering and Applied Chemistry from the University of Toronto, which he completed between 2008 and 2012.1
Career Progression
Dr. Saadatmand's professional journey includes:
- Current Role: Principal Scientist at Vertex Pharmaceuticals2
- Previous Positions:
- Sr Engineer I at Biogen (April 2019 - Present)
- Senior Research Associate at University of Cincinnati Simulation Center (January 2017 - April 2019)
- Research Associate at University of Cincinnati Simulation Center (December 2015 - December 2016)1
Educational Background
- Ph.D.: Chemical Engineering and Applied Chemistry, University of Toronto (2008-2012)
- Master's: Chemical and Petroleum Engineering, University of Calgary (2005-2008)
- Bachelor's: Chemical Engineering, Mahshahr Azad University1
Research and Expertise
Dr. Saadatmand's research interests include:
- Fluid Mechanics
- Heat Transfer
- Drug Delivery
- Multiphase Flow
- Interfacial Tension3
Notable Achievements
Throughout his career, Dr. Saadatmand has demonstrated expertise in various areas:
- Designed parts of the VHTR and performed CFD modeling
- Contributed to cost savings in pilot plant design
- Conducted research on oil sands froth, relevant to the petroleum industry
- Published research on vibration-induced particle motion under microgravity14
Dr. Saadatmand is multilingual, with native proficiency in Persian and full professional proficiency in English.1
Highlights
I am excited to share that we just published a peer-reviewed journal article in Pharmaceutical Research that demonstrates the best practices to use computational fluid dynamics (CFD) simulations for mixing of biopharmaceutical products. This article titled “An Experimental and Computational Approach to Development of Mixing Processes for Miscible Liquids in Unbaffled Tanks” also clarifies some of the most common errors in using CFD in mixing studies, the ways to avoid them and demonstrates the use of surrogate solutions instead of the valuable drug product in at-scale mixing studies. Using the methods described in this article increases the accuracy and efficiency of the mixing studies in the biopharmaceutical industry and greatly reduces the costs of these studies. This article can be accessed from: https://lnkd.in/e2CYnRwd.
